重组人血管内皮抑制素联合化疗治疗晚期恶性肿瘤的临床研究  

The clinical research of endostar combined with chemotherapy on advanced malignancy

作　　者：吕霞[1] 肖莉[1] 周启明[1] 王馨[1] 苏安[1] 吴炜新[1] 吴辉塔[1] 

机构地区：[1]厦门大学附属中山医院肿瘤科,福建厦门361004

出　　处：《实用临床医药杂志》2011年第19期43-45,共3页Journal of Clinical Medicine in Practice

摘　　要：目的观察重组人血管内皮抑制素（恩度）联合化疗治疗晚期恶性肿瘤的临床疗效。方法对51例晚期恶性肿瘤患者进行恩度联合化疗治疗，恩度7．5mg/（m2·d）加入500mL生理盐水中静脉滴注，连续给药14d，休息7d，21d为1个周期，联合化疗的方法根据患者不同疾病给予不同的化疗方案。观察患者临床疗效及毒副反应。结果治疗2个周期后，非小细胞肺癌（NSCLC）患者临床受益率为83．9％，总收益率为80．4％；随访至2010年7月底止，共有18例患者仍然生存，33例死亡，其中31例NSCLC患者中，生存12例，死亡19例，中位生存期为14个月。毒副反应主要是与化疗相关的骨髓抑制，其中Ⅲ～Ⅳ度毒副反应的患者达17例（33．3％），其余无毒副反应均为I度或Ⅱ度。结论恩度联合全身化疗治疗晚期恶性肿瘤获得了较好的I临床收益率和生存期，且毒副反应均可以耐受，值得临床进一步推广应用。Objective To observe the clinical effect of recombinant human endostatin （endostar） combined with chemotherapy on advanced malignancy. Methods Fifty- one patients with advanced malignancy received endostar combined with chemotherapy. The dose of endostar was 7.5 mg/（m2· d） by adding 500 mL normal saline intravenously, continuous administration for 14 days, rest 7 days, and 21 days as one cycle. The clinical effect and adverse reactions were observed. Results After two cycles, the clinical benefit rate of non- small cell lung cancer （NSCLC） patients was 83.9% and the total clinical benefit rate was 80.4%. Up till to July, 2010, 18 cases survived and 33 cases died. Twelve eases with NSCLC survived, while 19 eases died. The median survival time was 14 months. The main adverse reaction was bone marrow suppreasion, 17 cases （33.3%） were degree III -IV. The other adverse reactions were degree I or II. Conclusion Endostar com- bined with chemotherapy on advanced malignancy showed higher clinical benefit rate and longer lifetime, and the adverse reactions are tolerable. It＇s worth to be popularized and applied in clinical therapy.

关 键 词：重组人血管内皮抑制素 化疗 晚期恶性肿瘤 临床研究 

分 类 号：R730.53[医药卫生—肿瘤]